Recent News

• 06.08.2026 - Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
• 05.07.2026 - Ascendis Pharma Reports First Quarter 2026 Financial Results
• 05.06.2026 - New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

Recent Filings

• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 3/A Initial statement of beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - SD Specialized disclosure report
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.12.2026 - 4 Statement of changes in beneficial ownership of securities